Adastra announces appointment of CEO of PipeDreemz Georges Routhier to Board of Directors

June 29th, 2019 – Adastra Labs Holdings Ltd. (“Adastra” or the “Company”) announces the appointment of Georges Routhier, CEO of PipeDreemz Inc., to the Adastra Board of Directors.  “I cannot overstate how significant Georges joining our Board is to the Adastra Team.  Georges is a pioneer in the legal cannabis industry in Canada and has blazed a trail for the rest of to follow.  As the CEO of PipeDreemz Inc., he and his team are responsible for the successful licensing of nearly 30 percent of the cannabis licence holders across Canada.  He will bring a wealth of knowledge and excellent industry insight to our governance,” noted Andy Hale CEO of Adastra.

Georges E. Routhier is the principal consultant and CEO at PipeDreemz Inc. Considered the premier consultant in licensing regulations, Routhier’s company, PipeDreemz Inc., has helped applicants navigate the complexities of the licensing process for six years. Routhier had a lengthy and distinguished career within the high technology sector and now brings his wealth of knowledge to the cannabis industry. His career spans senior leadership positions in sales, security, customer care, marketing, product development, professional services, and corporate development. Routhier sits on a number of cannabis company boards and is technical advisor to numerous cannabis organizations, providing industry knowledge, from regulatory affairs, security, growing, facility design, quality control, product management, marketing and sales.

Routhier has an intimate personal knowledge base of the efficacy of medical marijuana. He chose to use this to create production standards and a reputation throughout the sector as a ‘go-to’ source of valued council that is second to none in the industry.  His discovery of the benefits of medical marijuana was precipitated by an illness in his family in 2001. His resulting passion for growing world-class medical cannabis and making extracts has empowered him to help many patients from the previous Marijuana Medical Access Regulations (MMAR) program and gives him great insight into the patient and growing side. His experience as a licensed patient and licensed designated grower under the MMAR has shaped and driven his ambition to grow the best medical cannabis in the world and share his knowledge.

“I am very pleased to join the Adastra Board and look forward to seeing the company grow in the coming months as they forge ahead with their business plan,” commented Mr. Routhier.

Further Information

For further information, please contact:

Andy Hale, CEO

Email: info@adastralabs.ca

About Adastra Labs Holdings Ltd.

In Canada, Adastra (through its wholly owned subsidiaries, Adastra Labs Inc. and Chemia Analytics Inc.) is in the application process to become a Standard Processor and Analytical Testing Laboratory under the Cannabis Act administered by Health Canada, with licences to produce cannabis extracts and provide third party analytical testing services. These licences will further enable Adastra and its subsidiaries to produce, package, sell (wholesale), and export medically focused and recreational cannabis extract and concentrate products in Canada to other licensed entities and internationally in jurisdictions where medical cannabis extraction products are legal.

The Company’s operations include a facility in British Columbia, Canada. The Company is developing its 13,035 square feet facility to be fully devoted to standard processing and laboratory testing by late 2019, from which it expects to produce significant amounts of cannabis oil and/or hemp oil for the Canadian wholesale medical and recreational markets.

The Company will offer a suite of unique products under several existing consumer-focused brands, including tinctures, medicinal oils, concentrates, and when legalized, gel capsules and vaporizer pens. Through acquisition of existing cannabis extraction brands and careful development of its new brands, Adastra will be positioned to be a leader in branded, commercialized products in both the medical and adult-use markets across North America and internationally.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to:  Adastra’s expectations concerning an increase in its production capacity. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Adastra assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. SOURCE: Adastra Labs Holdings Ltd.

Scroll to Top